AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
The Benefits of Endocrine Therapy for High Risk Genes
Not a lot of women that are BRCA2 positive are going to want to get randomized to either bilateral mastectomy or tamoxifen. In the carrier study for the patients who had a Pout B2 mutation, the lifetime risk of developing breast cancer was 32%. So if you cut that by 40%, I can't exactly do the math, but you get into like 15 to 18% risk, lifetime risk. Non-mutation carrier, lifetime risk would be 12%. so you do get almost two kind of normal risk and certainly below that threshold of high risk.